Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923368 | 1.00 | KYNU (0.57) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL12942520 | 0.87 | ELANE (0.61) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL11567174 | 0.87 | ELANE (0.60) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL4163321 | 0.87 | ELANE (0.60) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL8740045 | 0.87 | ELANE (0.60) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL5076528 | 0.86 | ELANE (0.67) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL8587097 | 0.86 | ELANE (0.59) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL7397375 | 0.84 | ECE1 (0.59) | KYNUACE2LAP3TACR1CTRB1 | |
| SCHEMBL14981588 | 0.84 | ALDH1A1 (0.56) | KYNUELANEATMPRTN3ACE2 | |
| SCHEMBL10955973 | 0.82 | KYNU (0.56) | KYNUELANEPRTN3ACE2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6737416-B2 | THROMBOLYTIC AGENT HAVING HIGHER SAFETY | MEIJI SEIKA KAISHA LTD. (JP) | 2004-05-18 | — | — | US | disclosed |
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6576627-B1 | Such as 7-amino-2-((2-methyl-1-(3-phenylpropanoylamino)-propyl)hydroxyphosphinoyl) -methylheptanoic acid; thrombotic disease | MEIJI SEIKA KAISHA LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| EP-1152004-B1 | Phosphonic acid derivatives having carboxypeptidase B inhibitory action | MEIJI SEIKA KAISHA (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-1174434-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | MEIJI SEIKA KAISHA LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1152004-A1 | PHOSPHONIC ACID DERIVATIVES HAVING CARBOXYPEPTIDASE B INHIBITORY ACTIVITY | MEIJI SEIKA KAISHA LTD. (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119787-A1 | Phosphonic acid derivative having inhibitory activity against carboxypeptidase B | CPB1, RNPEP, CPN1 | KYNU 3943/4885ELANE 173/4885ATM 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.